{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-084094","form_type":"8-K","ticker":"ATNM","cik":"0001388320","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2022-12-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.407881+00:00","generated_at":"2026-06-20T21:23:23.857650+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Actinium shareholders approve 3.5M share increase for 2019 Plan; Shetty re-elected","bullets":["Shareholders approved an amendment to the 2019 Stock Plan increasing authorized shares by 3.5M to a total of 9,333,333 shares.","The proposal passed with 8,780,109 votes for, 8,533,767 against, and 103,453 abstentions, a narrow margin.","Ajit S. Shetty was elected as Class III director for a three-year term with 9,814,712 votes for and 2,964,185 against.","Shareholders ratified Marcum LLP as independent auditor for FY2022 with 16,368,122 votes for.","Non-binding advisory vote on executive compensation passed with 9,832,125 votes for."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-084094","json":"https://secwatch.observer/filing/0001213900-22-084094.json","markdown":"https://secwatch.observer/filing/0001213900-22-084094.md","text":"https://secwatch.observer/filing/0001213900-22-084094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390022084094/0001213900-22-084094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390022084094/ea171085-8k_actinium.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T21:23:23.857650+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a50f3cd1b0bfb4047297b89020a1cea99bb7956","claim":"Actinium Pharmaceuticals, Inc. shareholders approved Elect Ajit S. Shetty as Class III director.","evidence_excerpt":"(1) To elect Ajit S. Shetty as a Class III director to serve for a three-year term that expires at the 2025 Annual Meeting of Stockholders, or until his successor is elected and qualified or until his earlier resignation or removal: Director For Against Broker Non-Votes Ajit S. Shetty 9,814,712 2,964,185 4,892,640","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390022084094/0001213900-22-084094-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"5ef375636bd3fad049b804553f49d9c71fb5313a","claim":"Actinium Pharmaceuticals, Inc. shareholders approved Approve amendment to 2019 Plan to increase authorized shares.","evidence_excerpt":"(2) To approve an amendment to the Actinium Pharmaceuticals, Inc. 2019 Plan to increase the total number of shares of common stock authorized for issuance under such plan from 5,833,333 by 3,500,000, to a total of 9,333,333 shares to attract and retain the best available personnel and to support planned hiring efforts as the Company grows: For Against Withheld /Abstained Broker Non-Votes 8,780,109 8,533,767 103,453 4,892,640","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390022084094/0001213900-22-084094-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"c93b1c97fc4e3236aa74f76e9bfd4605f5064a3a","claim":"Actinium Pharmaceuticals, Inc. shareholders approved Ratify appointment of Marcum LLP as independent auditor at the 2022-12-31 meeting.","evidence_excerpt":"(3) To ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022: For Against Withheld /Abstained Broker Non-Votes 16,368,122 913,738 389,676 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390022084094/0001213900-22-084094-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-31"}],"fact_type":"shareholder_vote"},{"claim_id":"d28d234f19fb5621fb30eafcbd1dafd63c49c780","claim":"Actinium Pharmaceuticals, Inc. shareholders approved Approve non-binding advisory vote on executive compensation.","evidence_excerpt":"(4) To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers: For Against Withheld /Abstained Broker Non-Votes 9,832,125 2,559,430 387,341 4,892,640","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390022084094/0001213900-22-084094-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}